$TELO

Telomir Pharmaceuticals, Inc. (TELO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD) Findings Strengthen Telomir-Zn’s Oncology-Focused Platform While Demonstrating Broader Relevance of Its

Telomir (TELO) reported preclinical data showing its drug Telomir-Zn improved visual function and retinal structure in a zebrafish model of age-related macular degeneration (AMD). The treatment also reduced oxidative stress and restored DNA methylation patterns. Telomir remains focused on oncology, with Telomir-Zn in Phase 1/2 trials for triple-negative breast cancer.

Telomir Pharmaceuticals, Inc. (TELO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matter to a Vote of Security Holders. On September 11, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The record date for stockholders entitled to notice of and to vote at the Annua

Telomir Pharmaceuticals, Inc. (TELO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 Consulting Agreement This Consulting Agreement (this “Agreement”) is entered into as of June 6, 2026 (“Effective Date”) by and between Telomir Pharmaceuticals, Inc. (“Company”) and Andriy Mushak (“Consultant”). Company and Consultant may

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data showing that Telomir-Zn significantly improved survival and multiple endpoints in a Wilson's disease model. The study, published in Advances in Redox Research, demonstrated that Telomir-Zn reduced oxidative stress, hepatic copper burden, and tissue degeneration, while improving liver biomarkers and locomotor function. These findings support Telomir-Zn's biological activity in Wilson's disease and its broader mechanistic relevance across other diseases involving oxidative stress and dysregulated metal homeostasis, including Triple-Negative Breast Cancer.

Telomir Pharmaceuticals, Inc. (TELO) has finalized its acquisition of TELI Pharmaceuticals, Inc. on April 22, 2026, issuing 34,389,710 restricted common shares to former TELI shareholders. This acquisition, which included a $1 million contribution from Bayshore Trust with an option for an additional $4 million, consolidates all global rights to Telomir-1 under Telomir Pharmaceuticals. This move eliminates geographic fragmentation and provides unified control over the development and potential commercialization of Telomir-1 worldwide.

Telomir Pharmaceuticals announced the completion of its acquisition of TELI Pharmaceuticals, consolidating global rights to its lead drug candidate, Telomir-1. This transaction involved issuing restricted shares to former TELI shareholders and a $1 million contribution from Bayshore Trust, with a potential for an additional $4 million investment based on milestones. The acquisition aims to eliminate geographic fragmentation of the Telomir-1 platform and accelerate its development for conditions like triple-negative breast cancer.

Telomir Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for Telomir-1 (Telomir-Zn) to treat advanced and metastatic Triple-Negative Breast Cancer (TNBC). This first-in-class metal-modulating epigenetic therapy targets iron-dependent pathways and has shown preclinical efficacy and a favorable safety profile. The company plans to initiate a Phase 1/2 clinical trial following IND clearance to evaluate Telomir-1 as an oral monotherapy.

Telomir Pharmaceuticals Inc. (TELO) has announced it has regained compliance with Nasdaq Listing Rule 5620(a) following its 2025 Annual Meeting of Shareholders. This resolution stabilizes the company's Nasdaq listing status and removes uncertainty for investors. An analyst has rated TELO stock a Buy with an $8.00 price target.

Telomir Pharmaceuticals announced positive preclinical results for its investigational compound Telomir-1 in animal models of triple-negative breast cancer (TNBC), conducted in collaboration with BioReperia. Telomir-1 demonstrated statistically significant reductions in primary tumor growth in aggressive TNBC forms, both as a standalone treatment and in combination with paclitaxel. The company plans to continue towards investigational new drug (IND) submission and refine clinical trial strategies based on these findings.